User profiles for T. M. Hughes

Thomas M. Hughes

- Verified email at uv.cl - Cited by 7548

Timothy M. Hughes

- Verified email at wakehealth.edu - Cited by 6030

T. Michael D. Hughes

- Verified email at northsurgonc.com.au - Cited by 3206

Diabetic microvascular disease: an endocrine society scientific statement

…, R Klein, BEK Klein, TM Hughes… - The Journal of …, 2017 - academic.oup.com
Both type 1 and type 2 diabetes adversely affect the microvasculature in multiple organs. Our
understanding of the genesis of this injury and of potential interventions to prevent, limit, or …

[HTML][HTML] White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunities

…, KM Hayden, AM Helman, TM Hughes… - Alzheimer's & Dementia …, 2019 - Elsevier
White matter hyperintensities (WMHs) are frequently seen on brain magnetic resonance
imaging scans of older people. Usually interpreted clinically as a surrogate for cerebral small …

Vascular contributions to cognitive impairment and dementia (VCID): a report from the 2018 National Heart, Lung, and Blood Institute and National Institute of …

…, CB Schaffer, C Yuan, TM Hughes… - Alzheimer's & …, 2020 - Wiley Online Library
Vascular contributions to cognitive impairment and dementia (VCID) are characterized by
the aging neurovascular unit being confronted with and failing to cope with biological insults …

[HTML][HTML] Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

…, E Davy, N Bucay, L Renshaw-Gegg, TM Hughes… - cell, 1997 - cell.com
A novel secreted glycoprotein that regulates bone resorption has been identified. The protein,
termed Osteoprotegerin (OPG), is a novel member of the TNF receptor superfamily. In vivo, …

Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma

…, AL Hamilton, GJ Mann, TM Hughes… - Journal of Clinical …, 2011 - ascopubs.org
Purpose To assess the frequency and type of oncogenic BRAF mutations in metastatic
melanoma and correlate BRAF status with clinicopathologic features and outcome. Patients and …

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

…, LJ Stevens, JD Chappell, X Lu, TM Hughes… - Science translational …, 2020 - science.org
Coronaviruses (CoVs) traffic frequently between species resulting in novel disease outbreaks,
most recently exemplified by the newly emerged SARS-CoV-2, the causative agent of …

Vascular dysfunction—the disregarded partner of Alzheimer's disease

…, HM González, C Yuan, SN Lockhart, TM Hughes… - Alzheimer's & …, 2019 - Elsevier
Increasing evidence recognizes Alzheimer's disease (AD) as a multifactorial and heterogeneous
disease with multiple contributors to its pathophysiology, including vascular dysfunction…

Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms

…, J Gribble, AS George, TM Hughes… - Science translational …, 2022 - science.org
The nucleoside analog remdesivir (RDV) is a Food and Drug Administration–approved
antiviral for treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

[PDF][PDF] Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice

…, LJ Stevens, JD Chappell, X Lu, TM Hughes… - Cell reports, 2020 - cell.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of
the novel viral disease COVID-19. With no approved therapies, this pandemic illustrates the …

Association of shared decision-making on patient-reported health outcomes and healthcare utilization

TM Hughes, K Merath, Q Chen, S Sun, E Palmer… - The American Journal of …, 2018 - Elsevier
Background Shared decision-making (SDM) is a process that respects the rights of patients
to be fully involved in decisions about their care. By evaluating all available healthcare …